TQB2858

P2, N=7, Terminated, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | N=100 --> 7 | Not yet recruiting --> Terminated; The sponsor has decided to terminate this study based on the current clinical research status of dual antibody drugs and full communication with the investigators.

P1/2, N=8, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=147 --> 8 | Trial completion date: Dec 2023 --> Jun 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Sep 2023 --> Mar 2023; The sponsor has decided to terminate this study based on the current clinical research status of dual antibody drugs and full communication with the investigators.

P1, N=29, Terminated, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | N=104 --> 29 | Recruiting --> Terminated; Terminated due to the adjustment of sponsor's development strategies and pipeline.

The combination of PD-L1 and TQB2858 did not significantly improve the ORR in patients with recurrent osteosarcoma. However, it improved immunogenic responses in ASPS, even after progression upon anti-PD-1/PD-L1 therapy, with an acceptable safety profile. IHC profiling with pathway enrichment analysis may not have any predictive value for survival outcomes.

The combination of PD-L1 and TGF-β antibody TQB2858 did not significantly improve ORR in recurrent osteosarcoma. However, it did improve the immunogenic responses in ASPS even after progression upon anti-PD-1/PD-L1 therapy with an acceptable safety profile. IHC profiling with pathway enrichment analysis would have possibilities to have predictive value for survival outcome, necessitating further investigation to confirm.

P1, N=104, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

P1, N=104, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.